Skip to main content
. 2006 Sep;8(3):295–301. doi: 10.31887/DCNS.2006.8.3/mspedding

Figure 2. Reasons for stopping clinical development of 121 compounds in clinical trials carried out by seven British companies. PK, pharmacokinetics .

Figure 2.